PROVIDENCE - Immunolgy engineering biotech firm EpiVax Inc. is leading a National Institutes of Health-funded $5.8 million collaboration developing a protective vaccine against avian influenza A(H7N9), identified by the Centers for Disease Control and Prevention as posing the greatest pandemic risk according to the CDC’s Influenza Risk Assessment Tool. In people, H7N9 can cause a severe form of pneumonia…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.